Clinical Trial Search

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC — 17; 11 participants

Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001

Primary: Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio…

Primary: Composite Success — 40; 14; 39; 12 participants — p=<0.001

Primary: Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) — -24.20; -3.25 Percent Change — p=0.003

Primary: Street-crossing Ability — 2.7; 2.3; 2.6; 3.0 number of hits/close calls — p=<0.05

Primary: Number of Participants With Adverse Events — 4 participants

Primary: Change From Baseline on Clinical COPD Questionnaire (CCQ) Score — 1.8; 1.7; 1.7; 1.9 units on a scale

Primary: Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine — 1.53; 0.76; 0.47 Percentage increase from baseline — p=0.002

Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids

Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants

Primary: Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24); — 41; 67; 96; 65 percentage of participants

Primary: Progression-Free Survival (PFS) Time — 11.17; 6.90 Months. — p=0.0002

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1). — 1.134; 1.145 Liters